All In Biotech

Free tool

FAERS Monitor: Ebglyss

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761306 or its brand name (Ebglyss, Lebrikizumab-Lbkz). Reports on generic versions are filed under their own applications.

Reports

2,280

Serious

254

11% of reports

Hospitalization

66

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus264
  • injection site pain260
  • drug ineffective241
  • rash178
  • conjunctivitis154
  • dermatitis atopic149
  • eczema135
  • erythema109
  • dry skin79
  • incorrect dose administered72
  • ocular hyperaemia62
  • skin exfoliation62
  • urticaria61
  • condition aggravated56
  • eye pruritus52

Reports by year received

View as table
YearReports
20223
20235
202471
20251,020
20261,181

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,879 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
conjunctivitisSignal15477.266.211,424
dermatitis atopicSignal14926.122.43,576
eczemaSignal13523.920.32,933
eye pruritusSignal5214.310.9630
ocular hyperaemiaSignal6212.19.4619
injection site painSignal2607.87.01,562
skin exfoliationSignal626.85.3301
pruritusSignal2646.35.71,203
dry skinSignal795.54.4285
erythemaSignal1094.94.1337
rashSignal1783.83.3367
urticariaSignal613.42.6100
incorrect dose administeredSignal722.92.389
condition aggravated561.71.316
drug ineffective2411.71.571

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.